Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.6304 +0.0804 (+14.62%)
Official Closing Price Updated: 4:10 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Future of Healthcare Conference
Via Investor Brand Network
Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021
From Cybin Inc.
Via Business Wire
Cybin Announces FDA Approvals, Participation in Conference
Cybin (NYSE: 
Via Benzinga
Exposures Product Safety
Cybin Releases Q2 Financial Results
Cybin (NYSE: 
Via Benzinga
Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model
Cybin (NYSE:CYBN), a biotech company focused on progressing ... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key FDA Approvals, Participation in Psychedelics Conference
Via Investor Brand Network
Exposures Product Safety
Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress
The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Inc's (NYSE: CYBN) psychedelic-assisted psychotherapy with psilocybin for... 
Via Benzinga
Exposures Product Safety
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
From Cybin Inc.
Via Business Wire
Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Adelia Milestone Achievements
Via Investor Brand Network
Cybin Supports Psychedelic Treatment Clinic Through Grant
Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced it has awarded a grant for the first... 
Via Benzinga
NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved
Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Awards Grant for Psychedelic Treatment Clinic to Benefit Underserved Communities
Via Investor Brand Network
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities
From Cybin Inc.
Via Business Wire
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
Cybin 'One Step Closer' to Creating Best Therapy for Mental Health
Company releases positive results from a pre-clinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to... 
Via Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health
Via Investor Brand Network
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion... 
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited... 
Via Benzinga
Exposures Product Safety
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q2 Financial Results, Business Highlights
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September. 
Via Talk Markets
Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser
This article was originally published on Psychedelic Spotlight and appears here with permission. "Something that people used t... 
Via Benzinga
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways reported 
Via Talk Markets
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Transformative Training Program for Psychedelic Facilitators
Via Investor Brand Network
Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the 'Superior Molecule'
This article was originally published on 
Via Benzinga
Cybin CEO Presenting at Jefferies London Healthcare Conference
Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Jefferies London Healthcare Conference
Via Investor Brand Network
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
Shares plunged, despite a psilocybin-based drug reducing depression in a trial. 
Via Investor's Business Daily
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.